Screener
Rigel Pharmaceuticals RIGL fostamatinib — Revenue recognized
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept rigl:CollaborativeArrangementRevenueRecognized.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
FAQ
- What is Rigel Pharmaceuticals's fostamatinib — revenue recognized?
- Rigel Pharmaceuticals (RIGL) reported fostamatinib — revenue recognized of $300K in Q1 2026.
- How has Rigel Pharmaceuticals's fostamatinib — revenue recognized changed year-over-year?
- Rigel Pharmaceuticals's fostamatinib — revenue recognized decreased by 25.0% year-over-year, from $400K to $300K.
- What is the long-term trend for Rigel Pharmaceuticals's fostamatinib — revenue recognized?
- Over 2 years (2021 to 2023), Rigel Pharmaceuticals's fostamatinib — revenue recognized has grown at a -76.1% compound annual growth rate (CAGR), from $10.5M to $600K.
- What does fostamatinib — revenue recognized mean?
- The total revenue earned from the sale or licensing of the fostamatinib product during the reporting period. This metric reflects the successful commercialization or milestone achievement associated with the drug. It serves as a primary indicator of the product's market adoption and financial contribution to the company.
Ask your AI about Rigel Pharmaceuticals's fostamatinib — revenue recognized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude